The stock of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has decreased by -1.77 when compared to last closing price of 20.34.Despite this, the company has seen a gain of 11.25% in its stock price over the last five trading days. globenewswire.com reported 2025-04-30 that WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m.
Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?
Additionally, the 36-month beta value for APLS is 0.73. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 3 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for APLS is 104.61M and currently, short sellers hold a 25.65% ratio of that float. The average trading volume of APLS on May 06, 2025 was 2.13M shares.
APLS’s Market Performance
APLS stock saw a decrease of 11.25% in the past week, with a monthly decline of -11.28% and a quarterly a decrease of -29.87%. The volatility ratio for the week is 5.84%, and the volatility levels for the last 30 days are 6.98% for Apellis Pharmaceuticals Inc (APLS). The simple moving average for the past 20 days is 6.65% for APLS’s stock, with a -32.97% simple moving average for the past 200 days.
Analysts’ Opinion of APLS
Many brokerage firms have already submitted their reports for APLS stocks, with Cantor Fitzgerald repeating the rating for APLS by listing it as a “Overweight.” The predicted price for APLS in the upcoming period, according to Cantor Fitzgerald is $44 based on the research report published on April 29, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see APLS reach a price target of $36. The rating they have provided for APLS stocks is “Neutral” according to the report published on December 17th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to APLS, setting the target price at $31 in the report published on November 21st of the previous year.
APLS Trading at -9.99% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.27% of loss for the given period.
Volatility was left at 6.98%, however, over the last 30 days, the volatility rate increased by 5.84%, as shares surge +0.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.40% lower at present.
During the last 5 trading sessions, APLS rose by +11.25%, which changed the moving average for the period of 200-days by -49.40% in comparison to the 20-day moving average, which settled at $18.73. In addition, Apellis Pharmaceuticals Inc saw -37.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Chopas James George, who sale 183 shares at the price of $24.82 back on Mar 17 ’25. After this action, Chopas James George now owns 47,955 shares of Apellis Pharmaceuticals Inc, valued at $4,543 using the latest closing price.
Chopas James George, the Officer of Apellis Pharmaceuticals Inc, proposed sale 183 shares at $24.82 during a trade that took place back on Mar 17 ’25, which means that Chopas James George is holding shares at $4,543 based on the most recent closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -0.21 for the present operating margin
- 0.85 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -0.25. The total capital return value is set at -0.24. Equity return is now at value -93.55, with -23.64 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.19. The debt to equity ratio resting at 2.06. The interest coverage ratio of the stock is -4.08.
Currently, EBITDA for the company is -154.53 million with net debt to EBITDA at -0.38. When we switch over and look at the enterprise to sales, we see a ratio of 3.29. The receivables turnover for the company is 2.88for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.25.
Conclusion
In conclusion, Apellis Pharmaceuticals Inc (APLS) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
